DexCom, Inc. $DXCM Shares Acquired by Retirement Systems of Alabama

Retirement Systems of Alabama grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 565.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 539,049 shares of the medical device company’s stock after acquiring an additional 457,986 shares during the period. Retirement Systems of Alabama’s holdings in DexCom were worth $46,515,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Fulcrum Asset Management LLP increased its holdings in DexCom by 3,769.0% during the 3rd quarter. Fulcrum Asset Management LLP now owns 5,494 shares of the medical device company’s stock worth $476,000 after acquiring an additional 5,352 shares during the period. Hohimer Wealth Management LLC increased its holdings in DexCom by 4.7% during the 3rd quarter. Hohimer Wealth Management LLC now owns 10,732 shares of the medical device company’s stock worth $926,000 after acquiring an additional 478 shares during the period. Ethic Inc. lifted its stake in DexCom by 0.7% in the 3rd quarter. Ethic Inc. now owns 23,744 shares of the medical device company’s stock worth $2,049,000 after purchasing an additional 172 shares in the last quarter. Alta Advisers Ltd purchased a new stake in DexCom in the 3rd quarter worth approximately $243,000. Finally, Kestra Advisory Services LLC lifted its stake in DexCom by 133.4% in the 3rd quarter. Kestra Advisory Services LLC now owns 12,786 shares of the medical device company’s stock worth $1,103,000 after purchasing an additional 7,309 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Down 1.4%

Shares of DXCM stock opened at $79.92 on Wednesday. The company has a quick ratio of 1.40, a current ratio of 1.74 and a debt-to-equity ratio of 0.49. The business has a 50-day moving average price of $84.79 and a two-hundred day moving average price of $75.08. DexCom, Inc. has a 12-month low of $55.84 and a 12-month high of $92.59. The firm has a market cap of $29.81 billion, a P/E ratio of 31.34, a price-to-earnings-growth ratio of 1.34 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The firm had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.61 EPS. Equities analysts anticipate that DexCom, Inc. will post 2.68 EPS for the current fiscal year.

Insider Transactions at DexCom

In related news, Director Nicholas Augustinos sold 6,539 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the completion of the sale, the director owned 29,293 shares in the company, valued at $2,461,783.72. The trade was a 18.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme M. Sylvain sold 3,638 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the sale, the executive vice president directly owned 146,828 shares of the company’s stock, valued at approximately $12,226,367.56. This represents a 2.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 22,822 shares of company stock worth $1,920,193. 0.28% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

DXCM has been the subject of several analyst reports. Evercore raised their price target on shares of DexCom from $90.00 to $110.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. Benchmark upped their price target on shares of DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Robert W. Baird set a $105.00 price target on shares of DexCom and gave the stock an “outperform” rating in a report on Friday, July 31st. Argus increased their price objective on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Citigroup lifted their price objective on DexCom from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $95.50.

DexCom Profile

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.